Carl Zeiss Meditec AG (ETR:AFX - Get Free Report) shares fell 3.1% on Wednesday . The stock traded as low as €59.95 ($68.91) and last traded at €60.00 ($68.97). 95,859 shares were traded during trading, an increase of 2% from the average session volume of 94,405 shares. The stock had previously closed at €61.95 ($71.21).
Carl Zeiss Meditec Trading Down 5.5%
The business has a fifty day simple moving average of €59.34 and a 200 day simple moving average of €56.38. The company has a quick ratio of 2.47, a current ratio of 2.13 and a debt-to-equity ratio of 7.41. The company has a market cap of $5.11 billion, a price-to-earnings ratio of 29.31, a P/E/G ratio of 2.83 and a beta of 0.98.
About Carl Zeiss Meditec
(
Get Free Report)
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders.
Further Reading
Before you consider Carl Zeiss Meditec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carl Zeiss Meditec wasn't on the list.
While Carl Zeiss Meditec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
